Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | CPA1 | P15085 | 2/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211254 | 0.85 | TAS1R3 (0.36) | ALDH1A1MMP1MMP2MMP3TSHR | |
| SCHEMBL5211819 | 0.82 | ALDH1A1 (0.35) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL8433762 | 0.81 | ALDH1A1 (0.37) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL5209568 | 0.79 | TAS1R3 (0.36) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL24855310 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL8157991 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL5209100 | 0.76 | — | — | |
| SCHEMBL5208547 | 0.74 | ALDH1A1 (0.38) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL5204535 | 0.73 | CA12 (0.46) | MMP1MMP2 | |
| SCHEMBL4895189 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958292-B1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AG (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20030162662-A1 | 2-Phenyl-2h-pyridazine-3-ones | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030130123-A1 | 2-Phenyl-2h-pyridazine-3-ones | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-10 | — | — | US | disclosed |
| EP-1272475-A1 | 2-PHENYL-2H-PYRIDAZINE-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1272476-A1 | 2-PHENYL-2H-PYRIDAZINE-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001079183-A1 | 2-PHENYL-2H-PYRIDAZINE-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079182-A1 | 2-PHENYL-2H-PYRIDAZINE-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-25 | — | — | WO | disclosed |
| US-6165944-A | 4-(3-heterocyclyl-1-benzoyl) pyrazoles and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0777658-B1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AG (DE) | 1999-12-15 | — | — | EP | disclosed |
| EP-0958292-A1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-24 | — | — | EP | disclosed |
| US-5885934-A | HERBICIDES OR FOR THE DESICCATION/DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| WO-1998031682-A1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-07-23 | — | — | WO | disclosed |
| WO-1996005179-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130123-A1 | 2-Phenyl-2h-pyridazine-3-ones | CNPY2, CBR3, CBR1 | ALDH1A1 439/4885MME 4032/4885ACE 2735/4885 |
| US-20030162662-A1 | 2-Phenyl-2h-pyridazine-3-ones | CNPY2, CBR3, CBR1 | ALDH1A1 768/4885MME 4131/4885ACE 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.